At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Transplantation of Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation or Cyclophosphamide/Fludarabine/Thiotepa/Total Body Irradiation Myeloablative Preparative Regimen
In Brief
A Phase 2 clinical trial evaluating Cyclophosphamide, Cyclosporine, and 7 other interventions for Acute Biphenotypic Leukemia and 18 related conditions. Completed, enrolled 135 participants across 3 sites.
Detailed Summary
This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic disease. Giving chemotherapy, such as cyclophosphamide and fludarabine, and TBI before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after transplant may stop this from happening.
Study Details
Timeline
Interventions
Given IV
Given IV and PO
Undergo double-unit UCBT
Given IV
Correlative studies
Given IV and PO
Undergo high-dose or moderate-intensity TBI
Undergo UCBT
Given IV